Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Jan:287:113978.
doi: 10.1016/j.jviromet.2020.113978. Epub 2020 Sep 23.

Determination of SARS-CoV-2 antibodies with assays from Diasorin, Roche and IDvet

Alexander Krüttgen  1 , Christian G Cornelissen  2 , Michael Dreher  2 , Mathias W Hornef  3 , Matthias Imöhl  1 , Michael Kleines  4
Affiliations
Comparative Study

Determination of SARS-CoV-2 antibodies with assays from Diasorin, Roche and IDvet

Alexander Krüttgen et al. J Virol Methods. 2021 Jan.

Abstract

There is an ongoing need for highly reliable serological assays to detect individuals with past SARS-CoV-2 infection. Using 75 sera from patients tested positive or negative by SARS-CoV-2 PCR, we investigated the sensitivity and specificity of the Liaison SARS-CoV-2 S1/S2 IgG assay (DiaSorin), the Elecsys Anti-SARS-CoV-2 assay (Roche), and the ID Screen SARS-CoV-2-N IgG indirect kit (IDVet). We determined a sensitivity of 95.5 %, 95.5 %, and 100 % and a specificity of 90.5 %, 96.2 %, and 92.5 % for the DiaSorin assay, the Roche assay, and the IDVet assay, respectively. We conclude that serologic assays combining very high sensitivity and specificity are still not commercially available for SARS-CoV-2. For maximizing sensitivity and specificity of SARS-CoV-2 serological diagnostics, the combination of two assays may be helpful.

Keywords: COVID-19; ELISA; SARS-CoV-2; Serology.

PubMed Disclaimer

Conflict of interest statement

We declare no conflict of interest

Figures

Fig. 1
Fig. 1
Time course of serological responses in two patients after onset of symptoms using different assay.
See this image and copyright information in PMC

References

    1. de Ory F., Guisasola M.E., Balfagon P., Sanz J.C. Comparison of commercial methods of immunoblot, ELISA, and chemiluminescent immunoassay for detecting type-specific herpes simplex viruses-1 and -2 IgG. J. Clin. Lab. Anal. 2018:32. - PMC - PubMed
    1. Eis-Hübinger A.M., Hönemann M., Wenzel J.J., Berger A., Widera M., Schmidt B., Aldabbagh S., Marx B., Streeck H., Ciesek S., Liebert U.G., Huzly D., Hengel H., Panning M. Ad hoc laboratory-based surveillance of SARS-CoV-2 by real-time RT-PCR using minipools of RNA prepared from routine respiratory samples. J. Clin. Virol. 2020;127 - PMC - PubMed
    1. Krüttgen A., Cornelissen C.G., Dreher M., Hornef M., Imöhl M., Kleines M. Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG. J. Clin. Virol. 2020;128 - PMC - PubMed
    1. Mallapaty S. Will antibody tests for the coronavirus really change everything? Nature. 2020;580:571–572. - PubMed
    1. Meyer B., Drosten C., Müller M.A. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus Res. 2014;194:175–183. - PMC - PubMed

Publication types